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Abstract
Background: Biomarkers play a key role in risk assessment, assessing treatment response, and detecting recurrence and the
investigation of multiple biomarkers may also prove useful in accurate prediction and prognosis of cancers.
Immunohistochemistry (IHC) has been a major diagnostic tool to identify therapeutic biomarkers and to subclassify breast
cancer patients. However, there is no suitable IHC platform for multiplex assay toward personalized cancer therapy. Here,
we report a microfluidics-based multiplexed IHC (MMIHC) platform that significantly improves IHC performance in reduction
of time and tissue consumption, quantification, consistency, sensitivity, specificity and cost-effectiveness.
Methodology/Principal Findings: By creating a simple and robust interface between the device and human breast tissue
samples, we not only applied conventional thin-section tissues into on-chip without any additional modification process,
but also attained perfect fluid control for various solutions, without any leakage, bubble formation, or cross-contamination.
Four biomarkers, estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), progesterone receptor (PR) and
Ki-67, were examined simultaneously on breast cancer cells and human breast cancer tissues. The MMIHC method improved
immunoreaction, reducing time and reagent consumption. Moreover, it showed the availability of semi-quantitative analysis
by comparing Western blot. Concordance study proved strong consensus between conventional whole-section analysis and
MMIHC (n=105, lowest Kendall’s coefficient of concordance, 0.90). To demonstrate the suitability of MMIHC for scarce
samples, it was also applied successfully to tissues from needle biopsies.
Conclusions/Significance: The microfluidic system, for the first time, was successfully applied to human clinical tissue
samples and histopathological diagnosis was realized for breast cancers. Our results showing substantial agreement
indicate that several cancer-related proteins can be simultaneously investigated on a single tumor section, giving clear
advantages and technical advances over standard immunohistochemical method. This novel concept will enable
histopathological diagnosis using numerous specific biomarkers at a time even for small-sized specimens, thus facilitating
the individualization of cancer therapy.
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Introduction
Accurate prediction and prognosis are the most critical and
difficult issues in breast cancer treatment. Because breast cancer, a
leading cause of cancer death in women, is a heterogeneous
disease that has several biological subtypes, single biomarker test is
insufficient to predict the clinical outcome of individual neoplasms
[1,2]. Many potential biomarkers with clinical value have been
identified through advances in genomics, proteomics, and
molecular pathology [3], and they have facilitated various kinds
of personalized therapy for cancer patients [4]. However, this
transition toward personalized therapy will require novel analyt-
ical methodology for accurate prediction and prognosis, particu-
larly multiplex analysis [5,6]. For example, genomic techniques
such as DNA microarray analysis (examining 4968 significant
genes) [7] and RT-PCR analysis of formalin-fixed, paraffin-
embedded tissues (examining 21 prospectively selected genes) [8]
have been used for chemotherapy treatment planning in breast
cancer. In addition, novel genetic and molecular classifications of
breast cancers have assisted in the individualization of adjuvant
systemic endocrine chemotherapy, and have reduced the severity
of side effects [1,9211]. However, although these genomic
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prognosis, significant changes in gene expression may not be
reflected in the level of protein expression or practical function
[12]. Therefore, to obtain a more accurate and sophisticated
understanding of patient status, the development of a novel
analytical method to detect various biomarkers at the proteomic
level is critical, in addition to analysis at the genomic level.
Immunohistochemistry (IHC) has been widely used for assessing
therapeutic biomarkers and has become a major part of practical
diagnosis for various malignancies in surgical pathology [13]. IHC
allows the identification of proteins of interest and provides
information on protein localization and tissue morphology [14]. In
addition, many studies showing the relationship between immu-
nohistochemical profiles and molecular classification of breast
cancers support that IHC might play a significant role in
subclassification of breast cancer patients [15,16]. Therefore,
IHC-based assays can represent an ideal method to realize
personalized-tailored therapies if efficient multiplexing method is
created. However, conventional IHC has been faced with several
practical limitations to examine tens of biomarkers in clinics: time,
labor, diagnostic expense, and the amount of tissues required. For
example, when various target proteins were examined by IHC for
precise prediction and prognosis such as Oncotype Dx which
examines over 20 genes involved in breast cancer [17], much time
and labors are required. Although an automated IHC machine is
able to overcome these issues, not only high costs from many
biomarkers but much tissue consumption still remain [3], which
might be significantly raised as practical problems for personalized
medicine. Moreover, qualitative evaluation, subjective decision
and variable result in IHC represent other hurdles toward a robust
and reputable proteomic tool [13].
Recently, multicolor-based IHC studies have been reported
with molecular dyes and quantum dots (QDs) for multiplexing
[18221]. Although the multicolor IHC including direct and
indirect sequential staining methods has a unique advantage of co-
expressions for biomarkers, several drawbacks are accompanied
depending on the multicolor staining method [22,23]. They
include low stability of primary antibodies from probe conjugation
process, alteration of binding properties, difficulty of probe
conjugation to antibodies, high cost of reagents, increases of time
and labors, and cross-over nonspecific binding of secondary
probes. Therefore, a parallel multiplexing approach is gaining the
interest as an alternative to overcome the limitations of multicolor-
based IHC and to enhance throughput of biomarker multiplexing.
Unfortunately, to date, few studies for parallel multiplexing
approach have been reported.
Here, we report a novel microfluidic parallel-multiplexed
immunohistochemistry (MMIHC) platform for the quantitative
pathological diagnosis of breast cancers. Since microfluidics
enables the formation of a well-confined microenvironment
[24,25], with fast and easy fluidic control [26] and the precise
manipulation of fluids [27230], not only the variation of
immunohistochemical staining, the amount of time and labor
required can be reduced via automation, but also multiple
biomarkers can be analyzed on a limited cancer core area. In
addition, because microfluidics uses much smaller volumes of
reagents and antibodies, it allows cost-effective diagnosis and
reduces financial burden of patients [31]. However, most
microfluidic devices have been fabricated by using an irreversible
bond between a microchannel and a glass slide, and only a few
studies have introduced the interface between tissue slide and a
microfluidic device; this also proves that few studies applied to
human clinical specimens have been reported in microfluidics. In
order to apply conventional thin-section tissues into on-chip
without any additional modification process, a tissue slide-
compatible assembler was developed for perfect compatibility of
conventional IHC method, which was robust and optimal in a
microfluidic device.
The goal of this study was to demonstrate significant
improvement of IHC performances in reduction of labor and
tissue consumption, quantification, consistency, sensitivity, speci-
ficity, cost-effectiveness, precise diagnosis and massive multiplex-
ing. By comparing the biomarker scores from MMIHC platform
with those of conventional whole-section analysis of breast cancer
tissues, the usefulness of MMIHC platform to predict patient
prognosis as well as to select drugs for chemotherapy was also
evaluated.
Results
Operation of the MMIHC Platform
The design of the MMIHC device took into consideration 1) the
number of solutions required for IHC, 2) the number of
representative biomarkers in breast cancer, and 3) the appropriate
reaction channel dimensions. We selected the biomarkers with the
most frequently used and the most significant indicators in
therapeutic decisions of breast cancers [21], so that estrogen
receptor (ER), human epidermal growth factor receptor 2 (HER2),
progesterone receptor (PR), and Ki-67 were chosen and thereby
four straight reaction channels were designed. Accordingly, the
device was composed of six reservoirs for reagents (R12R6), four
biomarker reservoirs (BR12BR4), individual microvalves for
reservoirs of reagents and biomarkers (RV12RV6 and biomarker
valve), four reaction channels, and one outlet (Figure 1A). Because
biomarkers are investigated within a localized area among whole
tissue in this approach, as in tissue microarray (TMA), the
dimensions of the reaction channels were considered with the
human breast tumor sample size in diameter and the partial area
representing a tissue result. Recent results provided by the
National Cancer Center of Republic of Korea have shown that
.93% of biopsy breast tissues had tumor sizes .4m m i n
diameter. Therefore, each reaction channel was 800 mm in width
and 5 mm in length to apply to most of tissue sections, giving an
area that was 14-fold larger than that of TMA with a 600-mm
diameter.
The MMIHC device was fabricated via two-step multilayer soft
lithography, poly(dimethylsiloxane) (PDMS; Sylgard 184; Dow
Corning, MA) replica molding and aligning processes. Creating an
appropriate interface between the MMIHC device and the tissue
slide was one of the most important works in realizing chip-based
MMIHC and minimizing tissue damage. A weight was set on top
of the device to provide constant pressure and to create a
reversible seal and a robust interface; in addition, this apparatus
was quick and easy to assemble as shown in Figure 1B. In the
assembly process of MMIHC assay, a tissue slide was loaded onto
the bottom plate. The tissue was soaked with washing buffer and
the plasma-treated MMIHC device having four reaction channels
(attached under the upper plate) was put on the tissue and then
aligned (Figure 1C). The MMIHC microchannels were filled with
the buffer and any creation of microbubbles was not allowed by
the process. To avoid any leakage from microchannels, a weight
was mounted on the upper plate, which the tissue was pressed by
the walls of microchannels and fluids were perfectly flowed along
the microchannels (Figure 1D).
Initially, deformation of reaction channels was doubted for
pressure because of elastic characteristic of PDMS, which might
cause different flow velocity profile for a reaction channel width.
However, z-stacked images obtained via confocal laser scanning
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reaction channels retained their original rectangular shape
reasonably well, and were completely separated between each
channel at 8 kPa (Figure S1A).
Tissue sample intactness was verified by white light scanning
interferometry (Pemtron Co., Korea). Although the tissue area
attached to the MMIHC device was damaged, tissue within the
reaction channels was intact; this intact region was the staining
area for scoring (Figure S1B). After characterization of the
MMIHC device, fluidic control for various solutions and
biomarkers was conducted. Even with a reversible seal, fluid flow
was perfectly controlled; at a flow rate of 300 mlh
21, solutions
were flushed completely from the reaction channel after only 5 s.
No leakage or bubble formation was observed even when the
device was located on a cell block. De-waxing in xylene,
rehydration, and heat-induced epitope retrieval (HIER) were
conducted off-chip, whereas most of antibody2antigen interaction
steps were performed on-chip. To enclose the stained tissue
sample, dehydration and mounting processes were conducted after
separating the MMIHC device from the slide.
Multiplexed IHC on a Cell Block
After aligning with a cell block (Figure 2A) and injecting various
solutions and biomarkers into the MMIHC device, IHC was
conducted on the chip. Four biomarkers, including ER, HER2,
PR, and Ki-67, were examined simultaneously on a MCF-7 cell
block. Each biomarker showed a different expression level, and the
pattern of immunohistochemical staining was equivalent to the
geometry of the reaction channels (Figure 2B). Because the
reaction channels were completely separated for each biomarker,
we were able to use the same label solution (containing 3,39-
diaminobenzidine tetrachloride [DAB]) for visualization of
immunological reactions for all biomarkers. Thus, parallel
multiplexing allowed rapid immunohistochemical staining and a
direct comparison of staining between biomarkers at one site. In
addition, this approach eliminated potential variation that may
occur as a result of multiple IHC steps. After counterstaining on
the chip, the slide was separated from the device without any
damage to the sample, and then stored using a conventional slide
storage procedure (Figure 2C).
Four breast cancer cell lines (AU-565, SK-BR-3, HCC70, and
MCF-7) were examined for ER, HER2, PR, and Ki-67
expressions. All breast cancer cell lines showed staining for the
indicated biomarkers at the appropriate cellular locations,
providing comparable results to those obtained via conventional
IHC (Figure 2D). In addition, biomarker staining was compared
quantitatively for each cell line using image analysis. Microscopic
images were analyzed based on the expectation-maximization
(EM) algorithm and the Gaussian mixture model (GMM) to
distinguish staining cells. Staining was presented as the expression
Figure 1. Configuration of a MMIHC platform. (A) Design of a MMIHC device. Reagent reservoirs (R12R6) with individual reservoir valves
(RV12RV6), biomarker reservoirs (BR12BR4) and four straight reaction channels were designed. After connecting a syringe pump to the outlet, the
solutions required for IHC were drawn through the reaction channels in the appropriate sequence (withdrawal pumping). Scale bar, 3 mm. (B)
Configuration of a MMIHC platform. When the microvalve controller modules were connected with the MMIHC device, the upper plate combined
with the MMIHC device was aligned with the tissue. Then, a weight was mounted on the upper plate to create a reversible seal. (C) Schematic of the
interface assembly between a MMIHC device and a tissue. (D) Magnified cross-sectional view of the area connecting a tissue and reaction channels of
the MMIHC device. The tissue is pressed by microchannel walls dividing reaction channels, perfectly forming microchannels without any leakage.
Different antibodies are flowed at each reaction channel and immunohistochemical staining for different biomarkers happened at every reaction
channel, but not the area pressed by the microchannel walls.
doi:10.1371/journal.pone.0010441.g001
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of the stained area and the average staining intensity. ER and PR
were expressed only in the MCF-7 cell line and HER2 was
expressed in AU-565 and SK-BR-3 cell lines. In contrast, Ki-67
was expressed in all cell lines (order of decreasing intensity: MCF-
7, AU-565, SK-BR-3, and HCC70; Figure 3A). IHC is generally
regarded as a qualitative method [13,32]; therefore, to validate
the quantitative ability of the MMIHC platform, the results
obtained above were compared to Western blotting results
(Figure 3B). Western blotting showed that ER and PR were
expressed only in the MCF-7 cell line, whereas HER2 was
expressed in AU-565 and SK-BR-3 cell lines and both expression
levels were similar as shown in MMIHC result. Ki-67 was
expressed in all cell lines, similarly to the result that came from
using the MMIHC platform; regression analysis showed that the
correlation coefficient between Western blotting and MMIHC
Figure 2. MMIHC using cell blocks. (A) Image of an MCF-7 cell block aligned with the MMIHC device. Scale bar, 500 mm. (B) Image processing
DAB reaction. The cell block was stained at discrete sites with ER, HER2, PR, and Ki-67 antibodies. Scale bar, 500 mm. (C) Completed cell block slide
after detachment from the platform. Samples were not damaged by the detachment process. Inset shows a magnified view. Scale bars, 3 mm. (D)
Comparison of immunohistochemical staining for ER, HER2, PR, and Ki-67 using conventional IHC versus the MMIHC platform (10006). The staining
quality of biomarkers using the MMIHC platform was comparable to that of the conventional method.
doi:10.1371/journal.pone.0010441.g002
Figure 3. Quantification of the MMIHC method. (A) Quantitative comparison of biomarker expression levels in AU-565, SK-BR-3, HCC70 and
MCF-7 breast cancer cell lines; mean 6 SD of four replicate assays per sample. (B) Western blotting of AU-565, SK-BR-3, HCC70 and MCF-7 cell lines for
four biomarkers.
doi:10.1371/journal.pone.0010441.g003
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blotting was consistent with our results for the MMIHC platform
and those of previous studies [33].
MMIHC had better repeatability than IHC for both automatic
and manual staining. To compensate systemic environment and
condition for MMIHC, manual IHC and automatic machine, the
expression levels were normalized by their mean value of each
biomarker (data not shown). The Levene’s test, one of the tests for
equal variance, was employed to compare the variances of
normalized expression levels for above three methods (with
significance level 0.05). The MMIHC had smaller variance than
IHC for automatic staining (Levene’s test: p-value=0.044).
Although the IHC for automatic staining had smaller variances
than for manual method, it was not statistically significant
(Levene’s test: p-value=0.595). This enhancement was likely the
result of automated staining within the confined environment of a
microfluidic system.
The MMIHC platform not only saved time and reagents, but
also improved efficiency of antibody2antigen reaction. The
semi-automated microfluidic platform completed IHC for the
four biomarkers within 90 min, which was a 10-fold decrease in
time required compared to conventional methods. In addition
to time and volumetric effects, the optimal antibody concen-
trations were also approximately 10-fold lower. Although
equivalent samples were used, staining intensity remained
similar to that obtained via conventional methods even when
the biomarkers were diluted 10-fold. To better understand this
phenomenon, we conducted computational fluid dynamics
(CFD) studies on the kinetics of receptor2ligand binding.
Under conventional IHC conditions, although the original
concentration was maintained on the tissue in the initial state,
the concentration of analyte exposed to the tissue was
significantly lower because the analyte in the vicinity of tissue
was bound to tissue receptors. In contrast, the concentration of
analyte showed very little change at the tissue surface when the
analyte was allowed to flow through the MMIHC platform.
Because the reaction rate of receptor2ligand binding is decided
by the absolute concentration of the analyte, and because mass
transport to an area with very low fluid velocity (i.e.,s u c ha st h a t
near to the tissue sample) is determined by the concentration
gradient, a high Reynolds number (Re)l i k e l yr e s u l t e di nt h e
continuous exposure of the initial analyte concentration and the
formation of a steep concentration gradient (Figure S2).
We also showed that staining was more intense after the same
incubation period when the flow rate was high (Figure 4A).
Quantification clearly showed that higher flow rates produced
higher expression levels for HER2 (Figure 4B). In addition,
expression levels at flow rates of 60 and 180 mlh
21 when using a
concentration of 0.16HER2 were similar to those obtained using
a conventional IHC method at a concentration of 16HER2; this
low concentration corresponded to the optimal antibody
concentration determined by a pathologist. Based on these results
and those of several other trials, we determined the optimal
incubation conditions for primary antibodies (flow rate,
100 mlh
21; incubation period, 10 min), which translate into a
.6-fold decrease in required time and 200-fold decrease in
antibody consumption.
MMIHC for Human Breast Cancer Tissues
After verifying the utility of MMIHC on a chip and examining
repeatability and the possibility of quantification using cell blocks,
we applied the platform to patient tumor tissues which are
heterogeneous in terms of morphology, genetic alterations and
histopathological features. Over one hundred cases of human
breast tumor tissues (115 cases) were randomly selected and the
distributions of the investigated biomarkers were not biased. All
experiments, including the MMIHC operation and clinical
analysis, were blindly conducted. A pathologist judged the cases
did not know not only the whole-section results of the cases but
also any information of cases tested by the MMIHC platform.
Unlike cell blocks, tissue samples are not homogeneous;
therefore, aligning the MMIHC device over the least heteroge-
neous area is critical for diagnostic outcome. The device was
aligned at the area of highest cancer cell density, which was
determined with the use of hematoxylin and eosin (H&E) staining
slide (Figure 5A). After that, we examined the biomarker
expression. Four biomarkers were examined simultaneously on
the same tissue sample. In contrast to the cell blocks, which
Figure 4. Staining efficiency as a function of incubation conditions. (A) Staining results for the SK-BR-3 cell line according to changes in flow
rate and HER2 antibody concentration (incubation time, 30 min). Stronger expression was observed at higher flow rates. (B) Quantitative evaluation
of HER2 expression under static and dynamic incubation conditions. As shown in the graph, the expression level of the 16 HER2 control
(conventional method) was not significantly different to that of 0.16HER2 at a flow rate of 60 mlh
21. The asterisk denotes statistically no significant
difference (p=0.395) between the indicated pair.
doi:10.1371/journal.pone.0010441.g004
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distinguish exact areas of biomarker staining because of tissue
heterogeneity and some weak or negative staining results. This was
resolved by injecting Mayer’s hematoxylin into the microchannels,
which clearly demarcated the reaction channels (Figure 5B).
Staining for the biomarkers was localized properly and score
values for biomarkers were also equivalent to that obtained via
conventional IHC (Figure 5C and 5D). Especially for PR, more
non-specific staining was shown in conventional automatic IHC
machine (Figure S3).
Although the biomarkers were examined in the areas in which
cancer was most severe, a comparative study was essential to
clarify whether the results from such a localized examination using
the MMIHC platform could be considered representative of the
whole tissue section. A blind experiment was performed and the
105 patient tissue slides investigated via MMIHC were scored by a
pathologist (Table S1). The results revealed that Kendall’s
coefficient of concordance (KCC, n=105) was 0.96 for ER, 0.90
for HER2, 0.95 for PR, and 0.98 for Ki-67; the agreement rates (k
coefficient, n=105) were 0.92, 0.65, 0.79 and 0.87 for ER, HER2,
PR, and Ki-67, respectively (Table 1). HER2 showed the lowest
KCC, although it should be noted that many cases for mismatches
were slight (scores of 0 versus 1+). PR also showed a lower match
rate than ER, which is consistent with previous studies showing
that PR had lower sensitivity, specificity, and overall k values than
ER [34].
After confirmation of concordance between whole tissue section
analysis and the MMIHC platform, we conducted the reproduc-
ibility study whether the platform also showed the same results
within tissues originated from the same patient. Six cases were
tested for reproducibility where four slides were made from the
breast tumor of the same patient. To verify the concern of tissue
Figure 5. Application of the MMIHC platform to human breast cancer tissues and comparison with conventional IHC. (A) The
alignment of MMIHC device with an H&E-stained tissue sample. The device was aligned at a site showing numerous stained nuclei, indicating an area
containing proliferating cancerous cells. Scale bar, 3 mm. (B) MMIHC image for a human breast cancer tissue sample. Compared to conventional IHC,
the image shows the expression of the four biomarkers (ER, HER2, PR, and Ki-67) simultaneously on a tissue slide. Scale bar, 500 mm. (C) Magnified
images of panel b (6400). (D) Images of ER, HER2, PR, and Ki-67 staining via conventional IHC. The expression of biomarkers and the assigned Allred
scores were equivalent.
doi:10.1371/journal.pone.0010441.g005
Table 1. Statistical concordance data for whole-section analysis versus the MMIHC platform (n=105), including Kendall’s
coefficient of concordance (KCC), x
2 test, k statistics, concordance and its 95% confidence interval (CI).
Kendall’s coefficient of
concordance (KCC) x
2 p-value k-value p-value % Concordance
95% confidence
interval (CI)
ER 0.96 200 ,0.0001 0.92 ,0.0001 98.1 93.3299.4
HER2 0.90 187 ,0.0001 0.65 ,0.0001 85.0 76.4291.0
PR 0.95 198 ,0.0001 0.79 ,0.0001 90.5 83.2295.3
Ki-67 0.98 204 ,0.0001 0.87 ,0.0001 91.4 84.4296.0
The KCCs were 0.96 for ER, 0.90 for HER2, 0.95 for PR, and 0.98 for Ki-67, and the agreement rates (k coefficient) were 0.92, 0.65, 0.79, and 0.87 for ER, HER2, PR, and Ki-67,
respectively. It is noted that KCC values .0.90 are regarded as almost perfect degree of agreement [45] and k values .0.61 are considered as substantial agreement
[34].
doi:10.1371/journal.pone.0010441.t001
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square of order 4 was used by cyclic permutation tests in the first
slides for subsequent slides to eliminate the sequential effect of
tests; ER, HER2, PR and Ki-67 for 1st slide, HER2, ER, Ki-67
and PR for 2nd slide, PR, Ki-67, ER and HER2 for 3rd slide, and
Ki-67, PR, HER2 and ER for 4th slide (Figure 6A). The
biomarkers and their score levels were expressed with colors and
their intensity (Figure 6B). The KCCs within appraiser showed
that all biomarkers had over 0.95 values by repetition of
measurement as all p-values are sufficiently small (Table S2). This
result indicates that the platform is also reproducible in tissue
sample and the sequence of the biomarkers does not affect score
results significantly.
Not all tissue samples were suitable for the MMIHC platform.
Although most tissues were firmly attached to the slides, tissue
detachment occasionally occurred after HIER. In total, about 9%
of the slides showed tissue detachment (10 cases among 115
samples). This problem is likely resolvable through optimization of
the sample preparation process, including fixation, sectioning, and
drying.
MMIHC on a Needle Biopsy Sample of Human Breast
Cancers for Precise Diagnosis in Early Stage
Preoperative chemotherapy has been used for large primary and
inflammatory breast cancers, and the examination of specific
biomarkers in needle biopsy samples greatly facilitates the early
individualization of neoadjuvant therapy [35]. Therefore, we
applied the platform on a tissue from needle biopsy of human
breast cancers, which reduced consumption of the rare tissues and
enabled investigation for more various biomarkers even in small-
sized samples. Despite the narrow area of core biopsy samples, the
MMIHC device was aligned easily and we were able to examine
the expression of four biomarkers on a single slide (Figure 7A). We
noted that fatty tissue (solid arrow in Figure 7A) should be avoided
when selecting an inspection window; biomarker expression in
such regions was inconsistent compared to other non-fatty areas
(dotted arrow in Figure 7A). Similar to cell blocks and tissue
samples, the four biomarkers were also expressed in needle biopsy
tissues (Figure 7B). A concordance study showed that the
agreement rate (Cohen’s k coefficient, n=8) was 1 for ER
(p=0.0001), 0.71 for HER2 (p=0.0175), and 0.73 for PR
(p=0.0044). In the case of tissues from needle biopsy, the k
statistics showed substantial agreement in concordance and ER
showed 100% concordance and HER2 and PR showed 87.5%
concordance (data not shown).
Discussion
The MMIHC platform, which was realized IHC on a chip and
was applied to human clinical tissues specimens for the first time,
minimized the use of externally connected equipment and formed
a simple interface with the tissue sample. The unique platform
significantly reduced the probability of assay failure (under 1%),
which is of critical importance in practical use when dealing with
clinically rare samples. Because the use of microfluidic channels
creates a confined microenvironment and staining was semi-
automated, MMIHC showed better repeatability of immunohis-
tochemical staining compared to conventional manual IHC
method and automatic IHC machine. This benefit seems to give
improvement for inconsistent problem of IHC. Furthermore, the
MMIHC yielded a 200-fold reduction of antibody consumption,
fast immunological reaction, and the ability to examine various
biomarkers for cancer chemotherapy in rare tissue samples. The
characteristics of MMIHC platform are expected to reduce costs
required for examination of various biomarkers when it is fully
developed with a full automated and high-throughput manner.
Quantitative scoring is one of the main topics to overcome
scoring subjectivity immunohistochemical analysis. By comparing
our results with those obtained via Western blotting, we showed
that the MMIHC platform is suitable for the semi-quantitative
analysis of cell blocks. In addition, since MMIHC enabled the
direct comparison of biomarker staining at a single site and
eliminated the unexpected variation that may arise from multiple
IHC steps, more accurate relative quantification was expected.
Because the inspection window for each biomarker is relatively
small, it would be also beneficial to perform quantification with
image analysis as same rationale with TMAs [36]. To adopt
automated quantitative image analysis into tissue results, however,
staining between ductal carcinoma in situ (DCIS) and invasive
Figure 6. Reproducibility study within tissues originated from the same patient. (A) Four slides were made from the human breast tumor
of the same patient and cyclic permutation tests were conducted; ER, HER2, PR and Ki-67 for 1st slide, HER2, ER, Ki-67 and PR for 2nd slide, PR, Ki-67,
ER and HER2 for 3rd slide, and Ki-67, PR, HER2 and ER for 4th slide. (B) Results of cyclic permutation tests for six cases. When the intensity of each
color is equivalent in the boxes, the case was perfectly matched. The black dotted square for Patient 4 denotes different intensity compared to others.
doi:10.1371/journal.pone.0010441.g006
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vances should be made in extensive image analyses and improved
algorithms to decide clear scores.
Although this platform has many advantages over the
conventional and automated machine-based IHC methods, it
was doubted whether the MMIHC results are consistent with
those obtained via conventional whole-tissue section analysis.
Actually, this was also a critical concern regarding the use of
TMA, which uses small tissue cores that may not be representative
of the whole tissue section. However, after publication of the initial
TMA results, many subsequent studies have shown excellent
correlation for various tumor types [37239]. Because the reaction
channel of the MMIHC device was 14-fold wider than the 600-mm
TMA core, it was expected to correlate well with the results of
conventional methods, although TMAs are advantageous in their
own right for permitting the selection of several tissue cores and
thus enhancing representativeness. As we expected, in statistical
aspect, results showed all of biomarkers showed over 0.90 KCC
values, reflecting the whole section IHC scores with almost a
perfect degree of agreement. This tendency was also shown in
tissue samples from needle biopsies.
In clinical aspects, the MMIHC method is likely to be no
detriment to patient care in clinical settings. Although there are
many reasons for discrepancy of scores between whole-section
analysis and MMIHC such as inborn errors with IHC itself
(intraobserver and interlaboratory variations), specimen selection,
processing and representativeness of MMIHC result, total cases
showing discordance in this study were 34 cases. Among our 34
discordant results, there were only two cases (case #27 and 93) of
disagreement between control and MMIHC for ER which did not
result in change of treatment plans (2+=.3+). For PR results,
three cases (case #7, 86, and 103) would result in a difference
when making treatment decisions. However, only one case (case
#103) could actually be treated differently since the ER status is
always considered simultaneously. The other seven cases (case
#18, 20, 30, 39, 59, 60, and 68) did not result in any change of
treatment plans (1+=.2+ or 3+=.2+). Most of the discordance
occurred in HER2 assessment. Specifically, two cases (case #28
and 69) among 16 discordant cases had potential risk for receiving
trastuzumab. In case #69, since HER2 2+ by automated
conventional method should be subsequently tested by fluores-
cence in situ hybridization (FISH) and treatment is dependent on
the FISH result. Three cases (case #26, 100, and 101) would
require additional FISH test. In summary, the cases that cause
clinically different treatment are 0 case for ER, 1 case for PR and 1
case for HER2, showing only 1.9% variation in clinical treatment.
Therefore, on the basis of our results, the MMIHC platform
showed sufficient possibility of adoption as a method for the
presentation of clinical specimens.
Another concern was the different scores depending on the
sequence of biomarkers owing to tissue heterogeneity. Cyclic
permutation test, however, revealed that scores of the biomarkers
were reproducibly repeated and the sequence of the biomarkers did
not affect score results significantly. This result is also likely to imply
that the aligning position is not such extremely critical; meaning that
the slight different position at the area of highest cancer cell density
was affordable in reproducibility. Although this study was conducted
in a microfluidic device with 800-mm-wide reaction channels to
satisfy so much as tissues having small cancer core, increasing the
width and number of the channels in different directions is expected
to enhance the representativeness of the results, in the same way that
the concordance of results obtained via TMA was improved by
increasing the number and size of the cores [39241].
In improving the standard of patient care, many issues must still
be resolved before the current format of the MMIHC platform can
compete with existing methods. Although the MMIHC approach
contains a sampling process within a whole section of tissue, it is
obvious that an assay that could accurately quantify several
cancer-related proteins simultaneously on single tumor section or
small tumor specimens does offer clear advantages and technical
advances over standard immunohistochemical method [21].
Therefore, a novel method showing substantial agreement for
KCC statistics is expected to be useful as a decision supporting tool
for pathologist and clinician.
InIHC,multiplexstaining isgrowingneed withinlimitedquantity
of clinical samples. Many studies for multiplex IHC have been based
on the multicolor approach [18221]. Sequential indirect multiplex-
ing method, which conducts blocking, antibody reaction and then
tagging with fluorescence in repeat, has an advantage to look at a
wide range of co-expressions for biomarkers. However, it is a labor
Figure 7. MMIHC on a needle biopsy sample of human breast cancers as a model of scarce tissue samples. (A) MMIHC image of a tissue
from needle biopsy of human breast cancers. The solid arrow indicates fatty tissue that showed less intense staining compared to non-fatty tissue
(dotted arrow). Scale bar, 500 mm. (B) Images of ER, HER2, PR, and Ki-67 expression in needle biopsy tissue (4006). Each biomarker was properly
stained and the result was consistent with those obtained via conventional IHC.
doi:10.1371/journal.pone.0010441.g007
Microfluidic Cancer Diagnosis
PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10441intensive and time consuming process, and might cause a cross-over
nonspecific binding of secondary probes as long as the serial
processing was increased [23]. In addition, it is not suitable for high-
throughputpurpose.Theseproblemscanbesolvedbydirectstaining
method, which each primary antibody is conjugated to a probe
showing a different color and a mixture of the probe conjugates was
exposed to a tissue sample in a single step. Although the approach
reduces time and labors, undesirable problems are confronted: 1)
some primary antibodies are not sometimes survived in the probe
conjugation process and their binding properties are often changed.
2) Probe conjugation to primary antibodies is hard when the original
antibody buffer contains serum or other proteins. 3) Reagent costs
can be considerably high whose issue prohibits clinical application
[22]. On the contrary, the parallel multiplexing method introduced
in this study significantly compensates direct and indirect sequential
multiplexing methods, so that it has several advantages: 1) reduction
of time consumption and labor intensiveness, 2) original elimination
of cross-over nonspecific tagging between biomarkers, 3) free
usability of conventional primary antibodies, and 4) cost-effective-
ness. In addition, the method has a potential to enhance throughput
when the direct or indirect sequential method was combined.
Moreover, to address the multiplexing and in situ quantification of
this new technology, tens of IHC assays are possible on a specimen
once the number of reaction channels is increased. It implies that the
MMIHC platform may be useful to confirm and complement the
results of similarly scaled genomic assays, such as the Oncotype DX
test (which also examines 21 factors), which will help to understand
the heterogeneous and complicated phenomena associated with
cancers.
The development of TMAs in 1998 [42] significantly acceler-
ated the process of validating biomarker expression in clinical
samples [43]. Although TMAs have many advantages over
conventional manual IHC methods, direct application to clinical
diagnosis has been restricted and TMA has remained a research
tool because of practical limitations, such as the requirement of fast
diagnostic results for urgent patients, sample damage, and tedious
procedures for tissue collection. However, our platform is almost
compatible to conventional IHC using a single thin-sectioned
tissue slide. Therefore, it is expected to support various potential
prognostic markers in clinical stage. As another aspect, because
MMIHC is essentially complementary to TMA (i.e., multiple
channels connected on top of a tissue slide rather than multiple
cores taken from different tissue samples on a single slide), it may
compensate for limitations associated with the latter method. For
example, by TMA use, current study has revealed that 27 IHC
markers proved to be significant prognostic indicators for 924
patients to predict disease outcome [44]. When the significant
indicators are investigated in research domain by TMAs, they are
practically able to be applied to patients by the platform. In
addition, it is expected to be a more effective and high-throughput
tool if the platform is combined with a TMA tissue slide that has 4-
mm core punctures. We anticipate a simple, fast, and quantitative
MMIHC platform will be broadly applicable to clinical diagnosis,
identification of novel markers for classifying solid tumors, the
selection of optimal biomarkers, development and screening of
IHC antibodies, biological pathway studies and establishment of
optimal IHC conditions (e.g., antibody concentration and incuba-
tion time) in various cancers.
Materials and Methods
Ethics Statement
Human tissue samples from each tumor lesion were obtained
from the National Cancer Center Hospital (Goyang, Korea) and
the Korea University Anam Hospital (Seoul, Korea), with the
corresponding written consents given by the patients or their
relatives. This study was approved by the Institutional Review
Board (IRB) at the National Cancer Center Hospital and Korea
University Anam Hospital.
Fabrication of a MMIHC Device
The fluidic channel mold for a MMIHC device was fabricated
via two-step multilayer soft lithography. To construct rectangular
reaction channels, SU-8 2025 (Microchem Corp., MA) was spin-
coated to form a 50-mm thick layer on a bare silicon wafer,
patterned by UV exposure. After developing the wafer, a masking
layer was patterned on the reaction channel area. To make a
round-shaped remnant fluidic channel, AZ 9260 was spin-coated
to form a 25-mm thick layer. After lifting off the masking layer, it
was exposed to UV light, and developed using AZ photoresist
developer. The fabricated mold was reflowed by heating, and the
fluidic channels were transformed into a round shape, except for
the reaction channels. The control channel mold was fabricated by
conventional SU-8 photolithography. After spin-coating the fluidic
channel mold with PDMS and curing, the fluidic channel was
aligned and bonded with the control channel using an O2 plasma
asher (270 W for 30 s).
Preparation of Cell Blocks and Tissues
Four commercially available breast carcinoma cell lines, MCF-
7, SK-BR-3, AU-565, and HCC70, were obtained from the
American Type Culture Collection (ATCC; Manassas, VA).
HCC70, MCF-7, and AU-565 were maintained in RPMI-1640
and SK-BR-3 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 100 IU ml
21 penicillin, and 100 mg ml
21 strepto-
mycin. All cell lines were cultivated at 37uC and incubated in 5%
CO2. Adherent cells were harvested by trypsinization before
reaching confluence. For IHC analysis, the harvested cells were
centrifuged, fixed in formalin, suspended in agar, and embedded
in paraffin to produce a cell block. Paraffin-embedded cell blocks
were sectioned at 4 mm thickness using a microtome (Leica,
Germany). The sections were baked onto positively charged slides
and allowed to dry for 1 h at room temperature, followed by 1 h in
an incubator at 60uC.
Tissue samples from each tumor lesion were fixed for 24 h in
4% neutral-buffered formalin, Bouin’s fixative, acetic formalin
alcohol (AFA), or 4% or 10% unbuffered formalin; 4 h in PreFer
(Anatech, Battle Creek, MI) or Pen-Fix (Richard Allen Scientific;
Kalamazoo, MI); or 48 h in 4% neutral-buffered formalin. After
paraffin embedding, tumor specimens were cut into 4-mm-thick
sections and allowed to dry for 1 h at room temperature, followed
by 1 h in an incubator at 60uC.
Immunohistochemical Staining
Four biological markers were investigated. ER (SP1) antibody
(Ventana, Tucson, AZ) and PR (1E2) antibody (Ventana) were
used in conventional methods at 16 concentration and in
MMIHC at a dilution of 1:10. HER2 oncoprotein antibody
(Dako, Denmark) was used in conventional methods at a dilution
of 1:500 and in MMIHC at a dilution of 1:5000. Ki-67 (clone
MIB-1) antibody (Dako) was used in conventional methods at a
dilution of 1:50 and in MMIHC at a dilution of 1:500. Cell blocks
and tissues were de-waxed in xylene and rehydrated through a
graded series of ethanol solutions. A microwave antigen-retrieval
technique was used and the samples were treated in target retrieval
solution, pH 9 (Dako), for 20 min at 750 W. The Cap-plus kit
(Zymed, San Francisco, CA) was used for immunostaining and
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Fremont, CA) was used for counterstaining.
Western Blotting
Protein was extracted from cells by the addition of lysis buffer
followed by centrifugation at 16,000 g for 10 min at 4uC. The
supernatant fractions were separated by polyacrylamide gradient
gel (8–16%) containing sodium dodecyl sulfate. Following
electrophoresis, the proteins were transferred to polyvinylidene
fluoride membranes (Millipore, Bedford). The membranes were
blocked in TBS-T (0.1% Tween 20) containing 5% non-fat milk
(Bio-Rad, Richmond) for 1 h at room temperature. After blocking,
the membranes were incubated for 2 h at room temperature with
primary antibodies against ER, HER2, PR, and Ki-67 (clone
MIB-1) antibodies. Then, the membranes were washed in TBS-T
(0.1% Tween 20), for 15 min at a time, and incubated with diluted
HRP-conjugated secondary antibody (Southern Biotech, Birming-
ham, AL) for 1 h at room temperature. This was followed by
washing with TBS-T (3615 min), incubation with WEST-ZOLH
plus chemiluminescence reagent (iNtRON Biotechnology, Korea)
for 1 min, and exposure to film (Kodak Blue XB-1, Rochester,
NY). The immunoblot of b-actin (R&D Systems, Korea) was used
as a loading control.
Image Acquisition and Analysis for Quantification of
MMIHC
Tissue images were taken in optimal condition considering
shading and glare. After completing MMIHC, the sample was
placedonaninvertedmicroscope (CarlZeiss,Germany)andimages
were acquired by a microscope CCD camera (Olympus DP71,
Japan) under 13,000 Lux light intensity. The microscope CCD
camera has 12.5 megapixels, 12-bit digital color that displays the
native CCD’s full-resolution live image at 15 frames per second.
The microscopic images were divided into three parts (Figure S4A):
the staining part (SP) of the cell, the non-staining part (NSP) of the
cell, and the background (Figure S4B). Then the expression level
was defined by multiplying the staining ratio and intensity, where
the staining ratio is the area ratio of the SP to the cell part (SP and
NSP) and the staining intensity is the average intensity in the SP. At
least five images were randomly taken along the individual reaction
channel via 4006magnification and theaverageexpressionlevelfor
the images was presented as a representative value of immunohis-
tochemical staining for a biomarker.
Bayesian classification was employed to segment a microscopic
image into the three parts based on their colors. The color
distribution of each part in RGB color space was represented by
the Gaussian mixture model (GMM), and estimated by the
expectation-maximization (EM) method. The probability density
function (PDF) of GMM with C components is defined as a convex
combination of Gaussian PDFs
px ;h ðÞ ~
X C
j~1
pjNx ;mj,
X
j
 !
ð1Þ
where N(x; m, g) is the d-dimensional Gaussian PDF with mean m
and the covariance g, and pj is the portion of the j-th component
such that 0,pj,1 for all components, and
PC
j~1 pj~1. The
parameter list
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X
1
,...,pC,mC,
X
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 !
ð2Þ
defines a particular PDF of the GMM. The parameters for the SP,
NSP, and background were obtained via the EM method using
data collected from IHC sample images. The numbers of clusters
in the GMM for the SP, NSP, and background were set at 5, 10,
and 2, respectively. Thirty independent IHC images were used to
train the PDF. The optimized Gaussian PDF was automatically
applied to the experimental images.
Data and Statistical Analyses
We compared the quantification of ER, HER2, PR, and Ki-67
expressions between MMIHC and the respective quantified
Western blot bands by using Pearson’s correlation. For ER and
PR, the Allred scores (028) assigned by a pathologist were
translated into negative (2) for 0 score, weak (+) for 2 and 3 scores,
intermediate (++) for 4, 5, and 6 scores, and strong (+++) for 7 and
8 scores. For HER2, we followed the HER-2/neu FDA-approved
scoring system and translated into (2) for 0, (+) for 1+,( ++) for 2+,
(+++) for 3+. For Ki-67, stained cell number was counted and
translated into (2) for #5%; (+) for 5%,x#20%; (++) for
20%,x#40%; (+++) for .40%. Attribute agreement analysis for
tissue data was performed using Minitab version 15. The relative
agreement between conventional IHC and MMIHC data for ER,
HER2, PR, and Ki-67 was assessed using KCC. Fleiss’ and
Cohen’s k statistics were calculated to evaluate the agreement
between the two systems, for which the contingency tables
between conventional IHC and MMIHC for ER, HER2, PR,
and Ki-67 are presented. Hypothesis testing was conducted using
the two sample t test to analyze HER2 and Ki-67 expression in the
four breast cancer cell lines.
Supporting Information
Table S1 Comparison of scores obtained via whole-section
analysis (control) versus the MMIHC platform in human breast
cancer tissues (n=105). For ER and PR: negative (2); weak (+);
intermediate (++); strong (+++). For HER2: score 0 (2); score 1 (+);
score 2 (++); score 3 (+++). For Ki-67: #5% (2); 5%,x#20% (+);
20%,x#40% (++); .40% (+++). The unit of tumor size is
centimeter. DCIS, ductal carcinoma in situ.
Found at: doi:10.1371/journal.pone.0010441.s001 (0.92 MB
DOC)
Table S2 Statistical concordance table of cyclic permutation
test, including KCC, x
2 test and p-value. Six cases were tested for
reproducibility where four slides were made from the breast tumor
of the same patient (total number of tissues: 24). The KCCs were
1.00 for ER, 1.00 for HER2, 1.00 for PR, and 0.96 for Ki-67,
respectively. The cyclic permutation tests indicate that the
MMIHC platform is reproducible in tissue sample and the
sequence of the biomarkers does not affect score results
significantly.
Found at: doi:10.1371/journal.pone.0010441.s002 (0.76 MB
DOC)
Figure S1 Characterization of the MMIHC platform. (A) Plane
and z-stacked confocal laser microscopy images of the reaction
channel area under 8 kPa. Reaction channels retained their
original rectangular shape and each was separated completely. (B)
Surface image of a cell block visualized using white light scanning
interferometry. Cells in the reaction channels were intact under
pressure, except for those in areas in direct contact with the
MMIHC device.
Found at: doi:10.1371/journal.pone.0010441.s003 (0.25 MB TIF)
Figure S2 Computational fluid dynamics (CFD) study examin-
ing the kinetics of receptor-ligand binding. (A) Concentration
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state after 80 s). The red dotted line indicates a tissue sample with
antigens. The analyte concentration in the vicinity of the tissue
decreased with time because the tissue functioned as a sink. (B)
Concentration profile of the analyte using the MMIHC platform
(Re=4.3; transient state after 80 s). Fresh analyte flowed into and
was maintained in the vicinity of the tissue; therefore, the
concentration of the analyte showed little decrease at the tissue
surface as time progressed. (C) Concentration distribution of the
analyte according to incubation conditions. The concentration
profiles between a non-flowing microchannel and the conventional
method were similar, and the concentration of the analyte exposed
to the tissue was higher when the flow velocity of the analyte
increased. (D) Concentration gradient versus analyte incubation
conditions. When the flow velocity was high, diffusion of the
analyte was dominant.
Found at: doi:10.1371/journal.pone.0010441.s004 (0.21 MB TIF)
Figure S3 Images of immunohistochemical staining for PR. (A)
An image of PR staining from automatic machine (6400). (B) An
image of PR staining from the MMIHC platform (6400). Blue
solid arrows indicate non-specific staining. Normally, more non-
specific staining was shown in conventional automatic IHC
machine.
Found at: doi:10.1371/journal.pone.0010441.s005 (0.68 MB TIF)
Figure S4 Image analysis of biomarker expression level. (A) A
microscopic image acquired via MMIHC. (B) The image was
divided into three parts: the staining part (SP), the non-staining
part (NSP), and the background. Only the cell area (SP and NSP)
was considered to minimize the variation of expression level
according to cell density. (C) Image after analysis. Only the brown-
colored areas remained.
Found at: doi:10.1371/journal.pone.0010441.s006 (0.36 MB TIF)
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